Involvement of E-cadherin, β-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma
Summary Background A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site. Objectives To investigate...
Saved in:
Published in: | British journal of dermatology (1951) Vol. 157; no. 6; pp. 1212 - 1216 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford, UK
Blackwell Publishing Ltd
01-12-2007
Blackwell |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Summary
Background A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site.
Objectives To investigate whether dysregulation of cell motility (Cdc42 expression), escaping the control of cell–cell and cell–matrix interactions (E‐cadherin, β‐catenin expression), enhances melanoma progression, and whether chemokine receptors (CXCR4) mediate cell migration and activation during invasion and metastasis development.
Methods The immunohistochemical expression of Cdc42, E‐cadherin, β‐catenin and CXCR4 was investigated in 30 patients with surgically treated nodular melanoma, 18 alive and disease free and 12 with a fatal outcome due to metastatic disease.
Results E‐cadherin expression was significantly reduced (P < 0·05) and cytoplasmic β‐catenin was increased in the patients who had died compared with disease‐free individuals, while membrane expression of β‐catenin was similar in the two groups. Patients with fatal outcome had increased Cdc42 (P < 0·01) and CXCR4 (P < 0·05). In this group a positive correlation was found between melanocytic Cdc42 expression and Breslow thickness (r = 0·598, P < 0·05) and between CXCR4 expression and Breslow thickness (r = 0·583, P < 0·05).
Conclusions Findings suggest that primary cutaneous melanoma with a high Breslow thickness is characterized by tumour cells with high motility and invasion ability, in line with the hypothesis that low E‐cadherin levels and overexpression of Cdc42 and CXCR4 could be prognostic markers of poor outcome. |
---|---|
AbstractList | Summary
Background A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site.
Objectives To investigate whether dysregulation of cell motility (Cdc42 expression), escaping the control of cell–cell and cell–matrix interactions (E‐cadherin, β‐catenin expression), enhances melanoma progression, and whether chemokine receptors (CXCR4) mediate cell migration and activation during invasion and metastasis development.
Methods The immunohistochemical expression of Cdc42, E‐cadherin, β‐catenin and CXCR4 was investigated in 30 patients with surgically treated nodular melanoma, 18 alive and disease free and 12 with a fatal outcome due to metastatic disease.
Results E‐cadherin expression was significantly reduced (P < 0·05) and cytoplasmic β‐catenin was increased in the patients who had died compared with disease‐free individuals, while membrane expression of β‐catenin was similar in the two groups. Patients with fatal outcome had increased Cdc42 (P < 0·01) and CXCR4 (P < 0·05). In this group a positive correlation was found between melanocytic Cdc42 expression and Breslow thickness (r = 0·598, P < 0·05) and between CXCR4 expression and Breslow thickness (r = 0·583, P < 0·05).
Conclusions Findings suggest that primary cutaneous melanoma with a high Breslow thickness is characterized by tumour cells with high motility and invasion ability, in line with the hypothesis that low E‐cadherin levels and overexpression of Cdc42 and CXCR4 could be prognostic markers of poor outcome. A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site. To investigate whether dysregulation of cell motility (Cdc42 expression), escaping the control of cell-cell and cell-matrix interactions (E-cadherin, beta-catenin expression), enhances melanoma progression, and whether chemokine receptors (CXCR4) mediate cell migration and activation during invasion and metastasis development. The immunohistochemical expression of Cdc42, E-cadherin, beta-catenin and CXCR4 was investigated in 30 patients with surgically treated nodular melanoma, 18 alive and disease free and 12 with a fatal outcome due to metastatic disease. E-cadherin expression was significantly reduced (P < 0.05) and cytoplasmic beta-catenin was increased in the patients who had died compared with disease-free individuals, while membrane expression of beta-catenin was similar in the two groups. Patients with fatal outcome had increased Cdc42 (P < 0.01) and CXCR4 (P < 0.05). In this group a positive correlation was found between melanocytic Cdc42 expression and Breslow thickness (r = 0.598, P < 0.05) and between CXCR4 expression and Breslow thickness (r = 0.583, P < 0.05). Findings suggest that primary cutaneous melanoma with a high Breslow thickness is characterized by tumour cells with high motility and invasion ability, in line with the hypothesis that low E-cadherin levels and overexpression of Cdc42 and CXCR4 could be prognostic markers of poor outcome. BACKGROUNDA key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed as a consequence of the disruption of homeostatic mechanisms in the skin of the original site.OBJECTIVESTo investigate whether dysregulation of cell motility (Cdc42 expression), escaping the control of cell-cell and cell-matrix interactions (E-cadherin, beta-catenin expression), enhances melanoma progression, and whether chemokine receptors (CXCR4) mediate cell migration and activation during invasion and metastasis development.METHODSThe immunohistochemical expression of Cdc42, E-cadherin, beta-catenin and CXCR4 was investigated in 30 patients with surgically treated nodular melanoma, 18 alive and disease free and 12 with a fatal outcome due to metastatic disease.RESULTSE-cadherin expression was significantly reduced (P < 0.05) and cytoplasmic beta-catenin was increased in the patients who had died compared with disease-free individuals, while membrane expression of beta-catenin was similar in the two groups. Patients with fatal outcome had increased Cdc42 (P < 0.01) and CXCR4 (P < 0.05). In this group a positive correlation was found between melanocytic Cdc42 expression and Breslow thickness (r = 0.598, P < 0.05) and between CXCR4 expression and Breslow thickness (r = 0.583, P < 0.05).CONCLUSIONSFindings suggest that primary cutaneous melanoma with a high Breslow thickness is characterized by tumour cells with high motility and invasion ability, in line with the hypothesis that low E-cadherin levels and overexpression of Cdc42 and CXCR4 could be prognostic markers of poor outcome. |
Author | Brancorsini, D. Pugnaloni, A. Giacchetti, A. Tucci, M.G. Zizzi, A. Lucarini, G. Ricotti, G. Biagini, G. |
Author_xml | – sequence: 1 givenname: M.G. surname: Tucci fullname: Tucci, M.G. organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy – sequence: 2 givenname: G. surname: Lucarini fullname: Lucarini, G. organization: Dipartimento di Neuroscienze, Istituto di Anatomia Patologica, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Lancisi-Salesi-Umberto I, Via Conca 71, 60020 Torrette, Ancona, Italy – sequence: 3 givenname: D. surname: Brancorsini fullname: Brancorsini, D. organization: Dipartimento di Neuroscienze, Istituto di Anatomia Patologica, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Lancisi-Salesi-Umberto I, Via Conca 71, 60020 Torrette, Ancona, Italy – sequence: 4 givenname: A. surname: Zizzi fullname: Zizzi, A. organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy – sequence: 5 givenname: A. surname: Pugnaloni fullname: Pugnaloni, A. organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy – sequence: 6 givenname: A. surname: Giacchetti fullname: Giacchetti, A. organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy – sequence: 7 givenname: G. surname: Ricotti fullname: Ricotti, G. organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy – sequence: 8 givenname: G. surname: Biagini fullname: Biagini, G. organization: U.O. Dermatologia, INRCA-IRCCS, Via della Montagnola 164, Ancona, Italy Istologia-Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Tronto 10/A, 60020 Torrette, Ancona, Italy |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19885948$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17970806$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkMtO3DAUhq2KCgbKK1TetKsmteP4tuiipEBBqJVGQLuzHOekZJo4NM7Q4bV4EJ6pDhnBtt74HJ3vP5d_H-343gNCmJKUxvdxlVImeJJRxtKMEJkSleUi3bxCi-fCDlqQWEqIFmwP7YewIoQywsku2qNSS6KIWKDuzN_17R104Efc1_g4cba6gaHxH_DjQ0xG8FNcVC7PsPUVLn4Wyxw3Ho83gG-H_tcAITS9fypOue9DE6Zebj1aD_064A5a6_vOvkGva9sGONz-B-jq5Piy-JpcfD89Kz5fJC5nXCSVzazUJK-F1NoJR3MurQJWungXU1aDjUdBlZUKCIFSWF1yJpkqK0Ym6AC9n_vGff6sIYyma4KDtp33MULxjDMiI6hm0A19CAPU5nZoOjvcG0rMZLVZmclRMzlqJqvNk9VmE6VvtzPWZQfVi3DrbQTebQEbnG3rwXrXhBdOK8V1riL3aeb-Ni3c__cC5uj8yxRFfTLrmzDC5llvh99GSCa5-fHt1Fwurynly3Nzwv4BGtiqsA |
CODEN | BJDEAZ |
CitedBy_id | crossref_primary_10_1111_pcmr_12544 crossref_primary_10_1111_j_1365_2133_2009_09107_x crossref_primary_10_1016_j_abb_2011_10_020 crossref_primary_10_1093_jnci_djp038 crossref_primary_10_1111_pcmr_12343 crossref_primary_10_1016_j_ccr_2011_10_030 crossref_primary_10_1021_bm400849n crossref_primary_10_1007_s00428_012_1309_9 crossref_primary_10_1016_j_canlet_2014_08_033 crossref_primary_10_3892_etm_2018_6413 crossref_primary_10_1016_j_urolonc_2015_03_016 crossref_primary_10_1111_bjd_14720 crossref_primary_10_3390_ijms23094775 crossref_primary_10_1016_j_pharmthera_2017_05_012 crossref_primary_10_1002_1878_0261_12433 crossref_primary_10_1111_j_1468_3083_2011_03978_x crossref_primary_10_1016_j_cyto_2024_156629 crossref_primary_10_1016_j_jid_2018_09_027 crossref_primary_10_1309_AJCP52YVYCTLUOPI crossref_primary_10_1002_mco2_144 crossref_primary_10_1111_bjd_12426 crossref_primary_10_1016_j_celrep_2022_110641 crossref_primary_10_1007_s10620_017_4451_z crossref_primary_10_1097_MNM_0000000000001806 crossref_primary_10_1002_ijc_30785 crossref_primary_10_1128_JVI_00590_15 crossref_primary_10_18632_oncotarget_7393 crossref_primary_10_1016_j_semcancer_2008_10_001 crossref_primary_10_1155_2020_8180261 crossref_primary_10_3390_cancers3010126 crossref_primary_10_17650_1726_9784_2020_19_4_8_17 crossref_primary_10_1038_s41598_017_10891_0 crossref_primary_10_1074_jbc_RA118_003290 crossref_primary_10_1007_s00403_013_1351_8 crossref_primary_10_1016_j_semcancer_2008_10_009 crossref_primary_10_1186_s12967_014_0305_z crossref_primary_10_3389_fcell_2020_575223 crossref_primary_10_1016_j_bbcan_2012_03_011 crossref_primary_10_1074_jbc_RA119_010077 crossref_primary_10_1016_j_acthis_2008_10_002 crossref_primary_10_1038_jid_2010_149 crossref_primary_10_1111_j_1365_2133_2008_09001_x crossref_primary_10_1016_j_fertnstert_2012_10_042 crossref_primary_10_1016_j_humpath_2014_06_018 crossref_primary_10_1007_BF03256334 crossref_primary_10_1177_0300985820934385 crossref_primary_10_4161_sgtp_29019 crossref_primary_10_1007_s10585_010_9368_2 crossref_primary_10_1016_j_cellsig_2011_04_001 crossref_primary_10_1371_journal_pone_0037317 crossref_primary_10_1111_j_1365_2133_2009_09395_x crossref_primary_10_1517_14728222_2013_828037 crossref_primary_10_1111_ajd_12023 crossref_primary_10_1016_j_semcancer_2008_10_012 crossref_primary_10_3892_or_2016_4618 crossref_primary_10_3389_fonc_2020_626129 crossref_primary_10_1038_onc_2013_194 crossref_primary_10_1111_j_1349_7006_2008_00997_x crossref_primary_10_1074_mcp_M112_027052 crossref_primary_10_3390_ijms18030586 crossref_primary_10_1038_jid_2012_421 crossref_primary_10_1016_j_rvsc_2020_04_007 crossref_primary_10_1038_s41598_022_21342_w crossref_primary_10_1074_jbc_M112_435941 crossref_primary_10_1002_cjp2_34 crossref_primary_10_1002_ijc_25452 crossref_primary_10_1111_pcmr_12379 crossref_primary_10_1016_j_ajpath_2012_07_009 crossref_primary_10_1620_tjem_2023_J091 crossref_primary_10_1093_carcin_bgt248 crossref_primary_10_1002_ijc_30245 crossref_primary_10_18632_aging_103054 crossref_primary_10_1038_srep29719 crossref_primary_10_1371_journal_pone_0086338 crossref_primary_10_3390_cells9061430 crossref_primary_10_1186_1471_2407_10_113 crossref_primary_10_1111_eci_13964 crossref_primary_10_3390_ijms25073956 crossref_primary_10_18632_oncotarget_15815 crossref_primary_10_1038_labinvest_2012_62 crossref_primary_10_1242_jcs_240135 crossref_primary_10_18632_oncotarget_10205 crossref_primary_10_1002_ptr_7587 crossref_primary_10_1111_j_1440_1827_2010_02548_x crossref_primary_10_3892_or_2017_5546 crossref_primary_10_18632_oncotarget_14687 crossref_primary_10_1016_j_bcp_2013_09_001 crossref_primary_10_1080_21541248_2016_1173767 crossref_primary_10_3109_1354750X_2013_781677 crossref_primary_10_1080_14737140_2021_1882860 crossref_primary_10_1007_s13277_014_2500_1 crossref_primary_10_1097_CCO_0b013e328337fe8f |
Cites_doi | 10.1038/35065016 10.1016/j.jdermsci.2004.03.002 10.1158/0008-5472.CAN-03-1757 10.1016/S0002-9440(10)65023-7 10.1038/70302 10.1111/j.1600-0560.2006.00601.x 10.1136/mp.52.3.151 10.1074/jbc.M106912200 10.1046/j.1365-2133.2003.05240.x 10.1038/bjc.1991.375 10.1111/j.1087-0024.2005.200407.x 10.1242/jcs.113.9.1535 10.1158/1078-0432.CCR-04-1887 10.1242/jcs.107.4.983 10.1097/00000658-197011000-00017 10.1006/scbi.2000.0362 10.1126/science.287.5458.1606 10.1016/j.fertnstert.2006.01.031 10.1016/S0014-5793(02)03698-0 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K 10.1158/1078-0432.CCR-03-0195 |
ContentType | Journal Article |
Copyright | 2008 INIST-CNRS |
Copyright_xml | – notice: 2008 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1111/j.1365-2133.2007.08246.x |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2133 |
EndPage | 1216 |
ExternalDocumentID | 10_1111_j_1365_2133_2007_08246_x 17970806 19885948 BJD8246 ark_67375_WNG_TRV115RJ_F |
Genre | article Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1CY 1OB 1OC 23N 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 5WD 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AABZA AACZT AAESR AAEVG AAHHS AAONW AAPGJ AAPXW AARHZ AASGY AAUAY AAVAP AAWDT AAXRX AAZKR ABCQN ABCUV ABEJV ABEML ABNHQ ABOCM ABPTD ABPVW ABQNK ABWST ABXGK ABXVV ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACFRR ACGFS ACMXC ACPOU ACPRK ACSCC ACUTJ ACXBN ACXQS ACZBC ADBBV ADEOM ADIPN ADIZJ ADKYN ADMGS ADOZA ADQBN ADVEK ADXAS ADZMN ADZOD AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFFNX AFGKR AFPWT AFYAG AFZJQ AGMDO AGQXC AGUTN AHEFC AIACR AIURR AIWBW AJAOE AJBDE AJEEA ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB APJGH ASPBG ATGXG ATUGU AVNTJ AVWKF AZBYB AZFZN AZVAB BAFTC BCRHZ BDRZF BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X H13 HF~ HVGLF HZI HZ~ IHE IX1 J0M J5H K48 KBYEO KOP L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OAUYM OCZFY OIG OJZSN OPAEJ OVD OWPYF P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL ROX RX1 SUPJJ TEORI TMA UB1 V9Y VVN W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI X7M XG1 Y6R YFH ZGI ZXP ZZTAW ~IA ~WT 08R AAPBV AAUGY AAVGM ABHUG ABPTK ABWRO ACSMX ACXME ADAWD ADDAD AFVGU AGJLS AKALU ALXQX BFHJK IQODW OBFPC SAMSI CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c4356-da2a7904f6799c6c1457a8e3bc13338a9ea963ed2b8e00eb6a9b53738bd30bc13 |
IEDL.DBID | 33P |
ISSN | 0007-0963 |
IngestDate | Fri Aug 16 22:01:55 EDT 2024 Fri Nov 22 01:13:41 EST 2024 Sat Sep 28 07:51:36 EDT 2024 Sun Oct 29 17:06:19 EDT 2023 Sat Aug 24 00:51:48 EDT 2024 Wed Oct 30 09:56:42 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | cutaneous melanoma Prognosis Dermatology CXCR4 Malignant tumor E-cadherin β-caten#m β Catenin Malignant melanoma Evolution Skin CXC chemokine E Cadherin Cancer Cdc42 |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4356-da2a7904f6799c6c1457a8e3bc13338a9ea963ed2b8e00eb6a9b53738bd30bc13 |
Notes | ArticleID:BJD8246 ark:/67375/WNG-TRV115RJ-F istex:5D24FF939F353D477390C1F31EB19CA6396D0B79 Conflicts of interest None declared. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17970806 |
PQID | 68525307 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_68525307 crossref_primary_10_1111_j_1365_2133_2007_08246_x pubmed_primary_17970806 pascalfrancis_primary_19885948 wiley_primary_10_1111_j_1365_2133_2007_08246_x_BJD8246 istex_primary_ark_67375_WNG_TRV115RJ_F |
PublicationCentury | 2000 |
PublicationDate | December 2007 |
PublicationDateYYYYMMDD | 2007-12-01 |
PublicationDate_xml | – month: 12 year: 2007 text: December 2007 |
PublicationDecade | 2000 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: London – name: Oxford – name: Edinburgh – name: England |
PublicationTitle | British journal of dermatology (1951) |
PublicationTitleAlternate | Br J Dermatol |
PublicationYear | 2007 |
Publisher | Blackwell Publishing Ltd Blackwell |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell |
References | Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis: a look outside the nucleus. Science 2000; 287:1606-9. Sanders DS, Blessing K, Hassan GA et al. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. Mol Pathol 1999; 52:151-7. Oyama T, Kanai Y, Ochiai A et al. A truncated β-catenin disrupts the interaction between E-cadherin and α-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res 1994; 54:6282-7. Tang A, Eller MS, Hara M et al. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci 1994; 107:983-92. Kassis J, Lauffenburger DA, Turner T, Wells A. Tumor invasion as dysregulated cell motility. Semin Cancer Biol 2001; 11:105-17. Jung ID, Lee J, Yun SY et al. Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility in A2058 melanoma cells. FEBS Lett 2002; 532:351-6. Murakami T, Cardones AR, Hwang ST. Chemokine receptors and melanoma metastasis. J Dermatol Sci 2004; 36:71-8. Hsu MY, Meier FE, Nesbit M et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000; 156:1515-25. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705-27. Robledo MM, Bartolomè RA, Longo N et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001; 276:45098-105. El-Bahrawy M, El-Masry N, Alison M et al. Expression of β-catenin in basal cell carcinoma. Br J Dermatol 2003; 148:964-70. Goteri G, Ciavattini A, Lucarini G et al. Expression of motility-related molecule Cdc42 in endometrial tissue of women with adenomyosis and ovarian endometriomata. Fertil Steril 2006; 86:559-65. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-8. Takeuchi H, Fujimoto A, Tanaka M et al. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004; 10:2351-8. Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 2005; 10:153-63. Silye R, Karayiannakis AJ, Syrigos KN et al. E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 1998; 186:350-5. Hsu M, Andl T, Li G et al. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci 2000; 113:1535-42. Scala S, Ottaviano A, Ascierto PA et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11:1835-41. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-6. Pecina-Slaus N, Zigmund M, Kusec V et al. E-cadherin and β-catenin expression patterns in malignant melanoma assessed by image analysis. J Cutan Pathol 2007; 34:239-46. Kawada K, Sonoshita M, Sakashita H et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004; 64:4010-17. Meier F, Satyamoorthy K, Nesbit M et al. Molecular events in melanoma development and progression. Front Biosci 1988; 3:D1005-10. Murakami T, Maki W, Cardones AR et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002; 62:7328-34. Eisenmann KM, McCarthy JB, Simpson MA et al. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1999; 1:507-13. Clark WH. Tumour progression and the nature of cancer. Br J Cancer 1991; 64:631-44. 2004; 64 2000; 113 2002; 532 2000; 156 1999; 1 2007; 34 2001; 276 2004; 10 2001; 410 1988; 3 2006; 86 2002; 62 1970; 172 2004; 36 1991; 64 2005; 10 1999; 52 2000; 287 1969; 29 2001; 11 2003; 148 1994; 107 2005; 11 1998; 186 1994; 54 b7_1005 b19_1017 b16_1014 b13_1011 Oyama T (b8_1006) 1994; 54 Meier F (b1_999) 1988; 3 b22_1020 b25_1023 b10_1008 b15_1013 b4_1002 b20_1018 b24_1022 Sanders DS (b3_1001) 1999; 52 Clark WH (b14_1012) 1969; 29 b17_1015 Clark WH (b2_1000) 1991; 64 Hsu M (b18_1016) 2000; 113 Tang A (b5_1003) 1994; 107 b9_1007 b11_1009 Hsu MY (b6_1004) 2000; 156 Murakami T (b12_1010) 2002; 62 b23_1021 b21_1019 |
References_xml | – volume: 113 start-page: 1535 year: 2000 end-page: 42 article-title: Cadherin repertoire determines partner‐specific gap junctional communication during melanoma progression publication-title: J Cell Sci – volume: 276 start-page: 45098 year: 2001 end-page: 105 article-title: Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells publication-title: J Biol Chem – volume: 10 start-page: 153 year: 2005 end-page: 63 article-title: Normal human melanocyte homeostasis as a paradigm for understanding melanoma publication-title: J Investig Dermatol Symp Proc – volume: 36 start-page: 71 year: 2004 end-page: 8 article-title: Chemokine receptors and melanoma metastasis publication-title: J Dermatol Sci – volume: 3 start-page: D1005 year: 1988 end-page: 10 article-title: Molecular events in melanoma development and progression publication-title: Front Biosci – volume: 11 start-page: 105 year: 2001 end-page: 17 article-title: Tumor invasion as dysregulated cell motility publication-title: Semin Cancer Biol – volume: 29 start-page: 705 year: 1969 end-page: 27 article-title: The histogenesis and biologic behavior of primary human malignant melanomas of the skin publication-title: Cancer Res – volume: 64 start-page: 4010 year: 2004 end-page: 17 article-title: Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes publication-title: Cancer Res – volume: 186 start-page: 350 year: 1998 end-page: 5 article-title: E‐cadherin/catenin complex in benign and malignant melanocytic lesions publication-title: J Pathol – volume: 532 start-page: 351 year: 2002 end-page: 6 article-title: Cdc42 and Rac1 are necessary for autotaxin‐induced tumor cell motility in A2058 melanoma cells publication-title: FEBS Lett – volume: 62 start-page: 7328 year: 2002 end-page: 34 article-title: Expression of CXC chemokine receptor‐4 enhances the pulmonary metastatic potential of murine B16 melanoma cells publication-title: Cancer Res – volume: 1 start-page: 507 year: 1999 end-page: 13 article-title: Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack‐1 and p130 publication-title: Nat Cell Biol – volume: 156 start-page: 1515 year: 2000 end-page: 25 article-title: E‐cadherin expression in melanoma cells restores keratinocyte‐mediated growth control and down‐regulates expression of invasion‐related adhesion receptors publication-title: Am J Pathol – volume: 34 start-page: 239 year: 2007 end-page: 46 article-title: E‐cadherin and β‐catenin expression patterns in malignant melanoma assessed by image analysis publication-title: J Cutan Pathol – volume: 148 start-page: 964 year: 2003 end-page: 70 article-title: Expression of β‐catenin in basal cell carcinoma publication-title: Br J Dermatol – volume: 11 start-page: 1835 year: 2005 end-page: 41 article-title: Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma publication-title: Clin Cancer Res – volume: 52 start-page: 151 year: 1999 end-page: 7 article-title: Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours publication-title: Mol Pathol – volume: 287 start-page: 1606 year: 2000 end-page: 9 article-title: Wnt signaling in oncogenesis and embryogenesis: a look outside the nucleus publication-title: Science – volume: 64 start-page: 631 year: 1991 end-page: 44 article-title: Tumour progression and the nature of cancer publication-title: Br J Cancer – volume: 54 start-page: 6282 year: 1994 end-page: 7 article-title: A truncated β‐catenin disrupts the interaction between E‐cadherin and α‐catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines publication-title: Cancer Res – volume: 86 start-page: 559 year: 2006 end-page: 65 article-title: Expression of motility‐related molecule Cdc42 in endometrial tissue of women with adenomyosis and ovarian endometriomata publication-title: Fertil Steril – volume: 172 start-page: 902 year: 1970 end-page: 8 article-title: Thickness, cross‐sectional areas and depth of invasion in the prognosis of cutaneous melanoma publication-title: Ann Surg – volume: 410 start-page: 50 year: 2001 end-page: 6 article-title: Involvement of chemokine receptors in breast cancer metastasis publication-title: Nature – volume: 107 start-page: 983 year: 1994 end-page: 92 article-title: E‐cadherin is the major mediator of human melanocyte adhesion to keratinocytes publication-title: J Cell Sci – volume: 10 start-page: 2351 year: 2004 end-page: 8 article-title: CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells publication-title: Clin Cancer Res – ident: b13_1011 doi: 10.1038/35065016 – ident: b23_1021 doi: 10.1016/j.jdermsci.2004.03.002 – ident: b25_1023 doi: 10.1158/0008-5472.CAN-03-1757 – volume: 156 start-page: 1515 year: 2000 ident: b6_1004 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)65023-7 contributor: fullname: Hsu MY – ident: b20_1018 doi: 10.1038/70302 – ident: b16_1014 doi: 10.1111/j.1600-0560.2006.00601.x – volume: 52 start-page: 151 year: 1999 ident: b3_1001 publication-title: Mol Pathol doi: 10.1136/mp.52.3.151 contributor: fullname: Sanders DS – volume: 29 start-page: 705 year: 1969 ident: b14_1012 publication-title: Cancer Res contributor: fullname: Clark WH – ident: b22_1020 doi: 10.1074/jbc.M106912200 – ident: b19_1017 doi: 10.1046/j.1365-2133.2003.05240.x – volume: 64 start-page: 631 year: 1991 ident: b2_1000 publication-title: Br J Cancer doi: 10.1038/bjc.1991.375 contributor: fullname: Clark WH – volume: 54 start-page: 6282 year: 1994 ident: b8_1006 publication-title: Cancer Res contributor: fullname: Oyama T – ident: b17_1015 doi: 10.1111/j.1087-0024.2005.200407.x – volume: 113 start-page: 1535 year: 2000 ident: b18_1016 publication-title: J Cell Sci doi: 10.1242/jcs.113.9.1535 contributor: fullname: Hsu M – ident: b21_1019 doi: 10.1158/1078-0432.CCR-04-1887 – volume: 107 start-page: 983 year: 1994 ident: b5_1003 publication-title: J Cell Sci doi: 10.1242/jcs.107.4.983 contributor: fullname: Tang A – ident: b15_1013 doi: 10.1097/00000658-197011000-00017 – ident: b9_1007 doi: 10.1006/scbi.2000.0362 – ident: b7_1005 doi: 10.1126/science.287.5458.1606 – volume: 3 start-page: D1005 year: 1988 ident: b1_999 publication-title: Front Biosci contributor: fullname: Meier F – ident: b11_1009 doi: 10.1016/j.fertnstert.2006.01.031 – ident: b10_1008 doi: 10.1016/S0014-5793(02)03698-0 – volume: 62 start-page: 7328 year: 2002 ident: b12_1010 publication-title: Cancer Res contributor: fullname: Murakami T – ident: b4_1002 doi: 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K – ident: b24_1022 doi: 10.1158/1078-0432.CCR-03-0195 |
SSID | ssj0013050 |
Score | 2.2790024 |
Snippet | Summary
Background A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of... A key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may be viewed... BACKGROUNDA key event in cancer metastasis is the migration of tumour cells from their original location to a secondary site. The development of melanoma may... |
SourceID | proquest crossref pubmed pascalfrancis wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1212 |
SubjectTerms | Adult Aged beta Catenin - physiology Biological and medical sciences Cadherins - physiology Cdc42 cdc42 GTP-Binding Protein - physiology Cell Proliferation cutaneous melanoma CXCR4 Dermatology Disease Progression E-cadherin Female Gene Expression Profiling Humans Immunohistochemistry - methods Male Medical sciences Melanoma - etiology Middle Aged Prognosis Receptors, CXCR4 - physiology Skin Neoplasms - etiology Tumors of the skin and soft tissue. Premalignant lesions β-catenin |
Title | Involvement of E-cadherin, β-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma |
URI | https://api.istex.fr/ark:/67375/WNG-TRV115RJ-F/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2133.2007.08246.x https://www.ncbi.nlm.nih.gov/pubmed/17970806 https://search.proquest.com/docview/68525307 |
Volume | 157 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5BkRAXyj_hp_iAOBHkTRzbOcJ2l7ISFVoK9GbZjiNV0ASartRjH4Fn4UH6EH0SZpzdLpF6QIhbrNhOPJ6xP9sznwGe54q74IRLC-54KiyqsS29S23hfUB8iyCWYod3Pqrdfb09IZqc2SoWpueHuNhwI8uI4zUZuHXd0MijhxYuspZMhDoT8hXhSVw0xGiO_MP6QIEXfTQK7cyh0g2dei6taDBTXSOhn5DnpO1QeHV_68VlsHSIcuM0Nd38nw28BTeXYJW97rXrNlwJzR24_n55HH8XfrxrcHSLjOPHrK3Z5Pz0p7dVDCl8yc5-xSSCckqNKy8yZpuKjffHc8EOGobYk0X_sJ4bJL6kdNN2Bx3V5xcIXUO76Nhh-Gab9tDeg0_Tyd54J13e4ZB6BGIyrWxmVclFLVVZeulHolBWh9x5bFaubRks9kaoMqcD58FJW7qC2JZclXPKdB82mrYJD4HJkVSI_1Sdi1qMXOZQOlWee8mzYLXVCYxW_WW-91Qd5o8lDuY2JEu6eFOZKEtzksCL2LEXBezRV3J1U4X5svvW7M0_I2Kez8w0ga1Bz6-_UGpNlDcJPFupgkELpWOXXkJG6iIrcChN4EGvIeuyqlSI2GUCMirCX_-2eTPbpqdH_1rwMdyIm9TRL-cJbBwfLcJTuNpVi61oN78Bpu0Ugw |
link.rule.ids | 315,782,786,1408,27933,27934,46064,46488 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5BKwEX_kvDT-sD4kRQNnFs5wjbXbZ_K7Qs0JtlO45UQZPSdKUeeQSehQfhIXgSZpzdLiv1gBC3WLGdeH7sz-OZMcDzTCbWW27jPLFJzA2KsSmcjU3unEd8iyCWYodH7-X4SO0MKE3O_iIWpssPcWlwI80I8zUpOBmkV7U8uGjhLmueilClXLxCQLnOBcolxXNk75ZHCknexaOQbQ7FbtWt58qeVtaqdSL7BflOmhbJV3X3XlwFTFdxbliohnf-6xDvwu05XmWvOwG7B9d8fR9uHM5P5B_A190aJ7iQdPycNRUb_Pr23ZkyRBW-ZD9_hCLicir1S8dTZuqS9Y_6E86Oa4bwkwUXsS49SHhJ5bppj1vqz80Qvfpm1rIT_8XUzYl5CB-Gg2l_FM-vcYgdYjERlyY1skh4JWRROOF6PJdG-cw6HFamTOENssOXqVU-SbwVprA5JVyyZZZQpQ1Yq5vabwITPSERAsoq4xXv2dQidcoscyJJvVFGRdBbMEyfdtk69B-7HKytiZZ096bUgZb6IoIXgbOXDczZZ_J2k7n-NH6rp5OPCJone3oYwdYK65dfKJSirDcRbC9kQaOS0slLRyEtVJ7mOJtG8KgTkWVbWUgE7SICESThr39bv9nboafH_9pwG26OpocH-mB3vP8EbgWbdXDTeQpr52cz_wyut-VsKyjRbydYGKs |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5BK1Vc-P8JP60PiBNB2cSxnSPsD-0Cq2op0JtlO45UQZPSdKUeeQSehQfhIXgSZpzdLpF6QIhbrNhOPJ6xP9sznwGeZjKx3nIb54lNYm5QjU3hbGxy5zziWwSxFDu8-17ODtVoTDQ501UsTMcPcbHhRpYRxmsy8JOy6ht58NDCRdaSiVClXLxAPLnJEZUTj36W7a9PFJK8C0ehrTnUur5Xz6U19aaqTZL6OblOmhalV3XXXlyGS_swN8xTkxv_s4U34foSrbKXnXrdgiu-vg1b75bn8Xfg616Nw1ugHD9jTcXGv759d6YMMYXP2c8fIYmonFLD0vGUmbpkw8PhnLOjmiH4ZMFBrCMHCS8pXTftUUv1uQViV98sWnbsv5i6OTZ34cNkfDDcjZeXOMQOkZiIS5MaWSS8ErIonHADnkujfGYdNitTpvAGe8OXqVU-SbwVprA50S3ZMkso0z3YqJvaPwAmBkIiAJRVxis-sKlF6ZRZ5kSSeqOMimCw6i990nF16D_WOJhbkyzp5k2pgyz1eQTPQsdeFDCnn8nXTeb60-y1Pph_RMg8n-pJBNu9nl9_oVCKOG8i2FmpgkYTpXOXTkJaqDzNcSyN4H6nIeuyspAI2UUEIijCX_-2fjUd0dPDfy24A1v7o4l-uzd78wiuhQ3r4KPzGDbOThf-CVxty8V2MKHfl2sXUQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Involvement+of+E%E2%80%90cadherin%2C+%CE%B2%E2%80%90catenin%2C+Cdc42+and+CXCR4+in+the+progression+and+prognosis+of+cutaneous+melanoma&rft.jtitle=British+journal+of+dermatology+%281951%29&rft.au=Tucci%2C+M.G.&rft.au=Lucarini%2C+G.&rft.au=Brancorsini%2C+D.&rft.au=Zizzi%2C+A.&rft.date=2007-12-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0007-0963&rft.eissn=1365-2133&rft.volume=157&rft.issue=6&rft.spage=1212&rft.epage=1216&rft_id=info:doi/10.1111%2Fj.1365-2133.2007.08246.x&rft.externalDBID=10.1111%252Fj.1365-2133.2007.08246.x&rft.externalDocID=BJD8246 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0963&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0963&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0963&client=summon |